ATRC Quote, Financials, Valuation and Earnings

Perspective Therapeutics, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -12425.36%. AtriCure, Inc.'s return on equity of -6.2% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

AtriCure, Inc. has a consensus price target of $51.44, signalling upside risk potential of 29.62%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than AtriCure, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.468, which suggesting that the stock is 46.788% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. AtriCure, Inc.'s net income of -$267K is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.66x versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX Ltd. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -862.39%. AtriCure, Inc.'s return on equity of -6.2% beat VolitionRX Ltd.'s return on equity of --.

AtriCure, Inc. has a consensus price target of $51.44, signalling upside risk potential of 29.62%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than AtriCure, Inc., analysts believe VolitionRX Ltd. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.468, which suggesting that the stock is 46.788% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. AtriCure, Inc.'s net income of -$267K is higher than VolitionRX Ltd.'s net income of -$5.4M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.66x versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of -1037.17%. AtriCure, Inc.'s return on equity of -6.2% beat Catheter Precision, Inc.'s return on equity of -192.05%.

AtriCure, Inc. has a consensus price target of $51.44, signalling upside risk potential of 29.62%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1496.69%. Given that Catheter Precision, Inc. has higher upside potential than AtriCure, Inc., analysts believe Catheter Precision, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.468, which suggesting that the stock is 46.788% more volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. AtriCure, Inc.'s net income of -$267K is higher than Catheter Precision, Inc.'s net income of -$2.3M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.66x versus 11.19x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings, Inc. has a net margin of -0.2% compared to AtriCure, Inc.'s net margin of 3.93%. AtriCure, Inc.'s return on equity of -6.2% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.

AtriCure, Inc. has a consensus price target of $51.44, signalling upside risk potential of 29.62%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Xtant Medical Holdings, Inc. has higher upside potential than AtriCure, Inc., analysts believe Xtant Medical Holdings, Inc. is more attractive than AtriCure, Inc..

AtriCure, Inc. has a beta of 1.468, which suggesting that the stock is 46.788% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.

AtriCure, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. AtriCure, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.

AtriCure, Inc. quarterly revenues are $134.3M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. AtriCure, Inc.'s net income of -$267K is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, AtriCure, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for AtriCure, Inc. is 3.66x versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.